WASHINGTON, D.C.—The White House said Friday that President Trump intends to nominate Texas oncologist Stephen Hahn to head the U.S. Food and Drug Administration, succeeding Scott Gottlieb, who stepped down in April, Bloomberg reports.
Hahn is chief medical executive of the MD Anderson Center at the University of Texas in Houston. Ned Sharpless, the former director of the National Cancer Institute, has been serving as acting commissioner in a term set to expire Friday, and he will return to his role as director of the National Cancer Institute.
Hahn’s nomination must be approved by the U.S. Senate, and until that happens, Brett Giroir, the assistant secretary for health at the U.S. Department of Health and Human Services, will serve as interim commissioner, said Health Secretary Alex Azar.
Hahn, 59, is experienced in the day-to-day practice of medicine and the operation of large health-care bureaucracies. Hahn has extensive research experience, having served as vice chairman for research in radiation oncology at the University of Pennsylvania’s Perelman School of Medicine and publishing more than 250 articles in medical journals.